Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:protein
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:KRAS_A146_T
gptkb:KRAS_G13_D |
| gptkbp:associated_with |
gptkb:healthcare_organization
|
| gptkbp:clinical_trial |
KRAS inhibitors
combination therapies target for cancer therapy targeting KRAS mutations |
| gptkbp:ecological_role |
driver mutation in cancer
|
| gptkbp:established |
adagrasib
sotorasib |
| gptkbp:family |
Ras protein family
|
| gptkbp:function |
regulates cell division
|
| gptkbp:genetic_diversity |
common in lung cancer
common in colorectal cancer common in pancreatic cancer |
| https://www.w3.org/2000/01/rdf-schema#label |
KRAS protein
|
| gptkbp:interacts_with |
gptkb:Raf-1
RAF proteins P I3 K |
| gptkbp:is_a_route_for |
Ras signaling pathway
Ras-Raf-MEK-ERK pathway P I3 K-AKT pathway |
| gptkbp:is_involved_in |
MAPK signaling pathway
Ras signaling pathway cell differentiation cell proliferation cell survival |
| gptkbp:is_represented_in |
upregulated in tumors
low in normal tissues high in colorectal cancer high in pancreatic ductal adenocarcinoma high in non-small cell lung cancer |
| gptkbp:location |
cell membrane
|
| gptkbp:modifications |
phosphorylation
farnesylation palmitoylation |
| gptkbp:promoter |
gptkb:KRAS
|
| gptkbp:research_focus |
drug development
biomarker for treatment response mechanisms of resistance oncogenic mutations therapeutic targeting |
| gptkbp:role |
signal transduction
|
| gptkbp:seed_dispersal |
12p12.1
|
| gptkbp:social_responsibility |
associated with Noonan syndrome
associated with Costello syndrome associated with cardio-facio-cutaneous syndrome |
| gptkbp:type |
gptkb:DJ
|
| gptkbp:weight |
approximately 21 k Da
|